🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Placebo

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule completed

    1 trial

  2. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Palliative Care

    phase 3 small molecule completed

    1 trial

  3. Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  4. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  5. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  6. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  7. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  8. Placebo 0 mg/1 mL Solution for infusion/injection, VAY736

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  9. Placebo ADCETRIS ( NaCl 0.9% 100 mL - Injection IV ), ADCETRIS 50 mg powder for concentrate for solution for infusion.

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  10. Placebo IRBESARTAN EG 150 mg, Irbesartan EG 150 mg comprimés pelliculés

    Pari Pharma GmbH

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  11. Placebo MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    3 trials

  12. Placebo Nasal Aerosol

    Teva Pharma GmbH

    Perennial Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  13. Placebo Spiromax

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule terminated

    1 trial

  14. Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  15. Placebo de PREDNISONE ARROW 20 mg, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Septic arthritis

    phase 3 small molecule active

    1 trial

  16. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  17. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  18. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  19. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  20. Placebo du FORXIGA 10 mg, Forxiga 10 mg film-coated tablets

    Pari Pharma GmbH

    Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.

    phase 3 small molecule active

    1 trial

  21. Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  22. Placebo for Acetylsalicylic Acid, ACETYLSALICYLIC ACID, REGN7508, Placebo for REGN7508

    Lacuna Pharma Pty Ltd

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  23. Placebo for Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation (FC)

    phase 3 small molecule completed

    1 trial

  24. Placebo for Mitapivat, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources